Molecular mechanisms of tamoxifen resistance;Aspects moleculaires des differents mecanismes de resistance au tamoxifene

Bulletin du Cancer

Volumn 84, Issue 1, 1997, Pages 69-75

  Bachmann Moisson, Nathalie ^a   Barberi Heyob, Muriel ^a   Merlin, Jean Louis ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

Author keywords

breast cancer; resistance; tamoxifen

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; DRUG METABOLISM; DRUG RESISTANCE; FEMALE; HORMONAL THERAPY; HUMAN; REVIEW; BIOAVAILABILITY; BREAST TUMOR; CHEMISTRY; GENE EXPRESSION; GENETICS; METABOLISM; MOLECULAR BIOLOGY; MUTATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MOLECULAR BIOLOGY; MUTATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 0030627178     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979; 27: 145-52.
2. Ali S, Metzger D, Bornert JM, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human estrogen receptor A/B region. EMBO 1993; 12: 1153-60.
3. Arnold SF, Obourn JD, Yudt MR, Carter TH, Notides AC. In vivo and in vitro phosphorylation of the human estrogen receptor. J Steroid Biochem Mol Biol 1995; 52: 159-71.
4. Bachmann-Moisson N, Barberi-Heyob M, Merlin JL, Ledrich ML, Batt AM, Guillemin F. Cytotoxicité du tamoxifène et de ses principaux métabolites sur lignées cellulaires d'adénocarcinomes mammaires humains. Bull Cancer 1996; 83: 809-15.
5. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995; 95: 39-47.
6. Cavailles V, Dauvois S, Danielian PS. Interaction of proteins with transcriptionally active estrogens receptors. Proc Natl Acad Sci 1994; 91: 10009-13.
7. Clarke R, Lippman ME. Acquisition of antiestrogen resistance in breast cancer. In: Drug resistance in oncology. New York: Beverly A. Teicher, 1993; 501-36.
8. Dana SL, Hoener PA, Wheeler DA. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol Endocrinol 1994; 8: 1193-207.
9. Denton RR, Koszewki NJ, Notides AC. Estrogen receptor phosphorylation. J Biol Chem 1992; 267: 7263-8.
10. Dowsett M, Johnston SRD, Haynes BP, Sacks NPM, Caum MB, Ebbs SR, Smith IE. Impaired intra-tumoral uptake as a mechanism for resistance in human breast cancer. Proc Am Assoc Cancer Res 1993; 34: 1463.
11. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 1996; 7: 351-9.
12. Fujimoto N, Katzenellenbogen BS. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol Endocrinol 1994; 8: 296-304.
13. Fuqua SAW, Fitzgerald SD, Chamness GC. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105-9.
14. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone CP. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990; 63: 1267-76.
15. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 8: 2147-53.
16. Halachmi S, Morden E, Martin G. Estrogen receptor-associated proteins: possible mediators of hormone induced transcription. Science 1994; 264: 1455-8.
17. Hirata S, Yamada-Mouri N, Nara M, Takisawa M, Ito H, Kato J. Presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. Endocr J 1995; 42: 289-93.
18. Hsieh JC, Jurutka PW, Galligan MA. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc Natl Acad Sci USA 1991; 88: 9315-9.
19. Hull DF, Clark GM, Osborne CK. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 413-9.
20. Jiang SY, Parker CJ, Jordan VC. A model to describe how a point mutation of the estrogen receptor alters the structure. Breast Cancer Res Treat 1993; 26: 139-47.
21. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994; 54: 349-53.
22. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem 1985; 22: 589-96.
23. Klein-Hitpass L, Kaling M, Ryffel GU. Synergism of closely adjacent estrogen-responsive elements increases their regulatory potential. J Mol Biol 1988; 201: 537-44.
24. Klinge CM, Peale FV Jr, Hilf R. Cooperative estrogen receptor interaction with consensus or variant estrogen responsive elements in vitro. Cancer Res 1992; 52: 1073-81.
25. Kon OL. An antiestrogen binding protein in human tissues. J Biol Chem 1983; 258: 3173-7.
26. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 1987; 51: 941-51.
27. Landel CC, Kushner PJ, Greene GL. The interaction of human estrogen receptor with DNA is modulated by receptor associated proteins. Mol Endocrinol 1994; 8: 1407-19.
28. Le Goff P, Montano MM, Schodin DJ. Phosphorylation of the human estrogen receptor. J Biol Chem 1994; 269: 4458-66.
29. LeDouarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P, Losson R. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J 1995; 14: 2020-33.
30. Leygue ER, Watson PH, Murphy LC. Estrogen receptors variants in normal human mammary tissue. JNCI 1996; 88: 284-90.
31. Martinez E, Wahli W. Cooperative binding of estrogen receptor to imperfect estrogen-responsive DNA elements correlates with their synergistic hormone dependent enhancer activity. EMBO J 1989; 8: 3781-91.
32. McCague R, Parr IB, Leclercq G, Leung O, Jarman M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol 1990; 39: 1459-65.
33. Murphy C, Fotsis T, Pantzer P. Analysis of tamoxifen, N-desmethyltamoxifen, and 4-hydroxytamoxifen levels in cytosol. J Steroid Biochem 1987; 28: 609-18.
34. Murphy CS, Langan-Fahey SM, McCague R. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol 1990a; 38: 737-43.
35. Murphy CS, Pink JJ, Jordan VC. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 1990b; 50: 7285-92.
36. Naar AM, Boutin JM, Lipkin SM. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 1991; 65: 1267-79.
37. Nuwaysir EF, Daggett DA, Jordan VC, Pitot HC. Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res 1996; 56: 3704-10.
38. Orti E, Hu LM, Munck A. Kinetics of glucocorticoid receptor phosphorylation in intact cells. J Biol Chem 1993; 268: 7779-84.
39. Osborne CK. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 1993; 47: 1-6.
40. Osborne CK, Corodano E, Allred DC, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumors levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991; 83: 1477-82.
41. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 1992; 10: 304-10.
42. Osborne CK, Fuqua SAW. Mechanisms of tamoxifen resistance. Br Cancer Res Treat 1994; 32: 49-55.
43. Parisot JP, Hu XF, Sutherland RL, Wakeling A, Zalcberg JR, DeLuise M. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor. Int J Cancer 1995; 62: 480-4.
44. Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, van Nagell JR Jr. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res 1992; 52: 4106-12.
45. Pham TA, Elliston JF, Nawaz Z. Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 1991; 88: 3125-9.
46. Philips A, Chalbos D, Rochefort H. Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 1993; 268: 14103-8.
47. Pink JJ, Jiang SY, Fritsch M, Jordan VC. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 1995; 55: 2583-90.
48. Ponglikitmongkol M, White JH, Chambon P. Synergistic activation of transcription by the human estrogen receptor bound to tandem responsive elements. EMBOJ 1990; 9: 2221-31.
49. Pratt WB. Interaction of hsp90 with steroid receptors: organizing some diverse obseravtions and presenting the newest concepts. Mol Cell Endocrinol 1990; 74: C69-C76.
50. Pratt WB, Czar MJ, Stancato LF. The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal-binding protein? J Steroid Biochem Mol Biol 1993; 46: 269-79.
51. Romagnolo D, Annab LA, Risinger JI, Terry LA, Lyon TT, Barrett JC. Regulation of expression of BRCA-1 by estrogen in breast MCF-7 and ovarian BG-1 cancer cells. Proc AACR 1996; 37: 516.
52. Scott G, Kushner P, Vigne JL, Benz CC. Truncated forms of DNA-binding estrogens receptors in human breast cancer. J Clin Invest 1991; 88: 700-6.
53. Smith DF, Toft DO. Steroid receptors and their associated proteins. Mol Endocrinol 1993; 7: 4-11.
54. Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast tumor. Anti-Cancer Drugs 1995; 6: 498-507.
55. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily. Annu Rev Biochem 1994; 63: 451-86.
56. Tsai SY, Tsai MJ, O'Malley BW. Cooperative binding of steroid hormone receptors contributes to transcriptional synergism at target enhancer elements. Cell 1989; 57: 443-8.
57. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994; 269: 16433-42.
58. Vickers PJ, Dickson RB, Shoemaker R, Cowan KH. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 1988; 2: 886-92.
59. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell. Mol Endocrinol 1995; 9: 443-56.
60. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 1992; 10: 990-4.
61. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC. Investigation of the mechanism of ramoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85: 806-12.
62. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variants contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994; 31: 129-38.